Sarepta Therapeutics (SRPT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Sarepta Therapeutics

NasdaqGS•Healthcare•Biotechnology

$19.76-0.96(-0.05%)Pre-market

Market Cap

$2.18B

P/S

1.1x

P/B

1.4x

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 38/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (4/25).

Profitability8/25

Growth4/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality11/25

Strengths

Long cash runway

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 33.1x5y range 33.1x – 714.2x

Currently below its 5-quarter median.

P/S · 1.1x5y range 0.0x – 12.3x

Currently below its 20-quarter median.

P/B · 1.4x5y range 0.0x – 29.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 942.0% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.18B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.97B
Q. Revenue: $401.25M
TTM EBITDA: $-98.54M
TTM Op. Income: $-143.25M
Q. Op. Income: $13.29M
TTM Net Income: $-136.72M
Q. Net Income: $-4.89M
EPS: $-0.05
Shares Out.: $105.43M

$1.97B in TTM revenue declined 20.4% YoY, reaching $401.25M last quarter. TTM EBITDA of $-98.54M and TTM operating income of $-143.25M show growth is flowing through to the bottom line. However, net income is negative at $136.72M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 4 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 5.9%
Op. Margin: 3.3%
Net Margin: -1.2%

Op. margin of 3.3% is down 15.6% YoY — costs are rising relative to revenue. Net margin at -1.2% Over the past year, operating margin is down 82% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.1x
P/B Ratio: 1.4x

P/S of 1.1x and P/B of 1.4x. P/S is low relative to typical market levels. Across the last 3 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.19B
Cash: $571.15M
Long-Term Debt: $847.62M
Book Value: $1.53B
D/E Ratio: 0.6
Debt/EBITDA: 35.8

With $3.19B in assets and $847.62M in long-term debt, D/E is 0.6and book value is $1.53B — a conservative capital structure with a cushion to weather downturns. Across the last 6 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $197.07M
TTM Free Cash Flow: $81.85M
FCF Margin: 4.1%
FCF / Net Income: -0.6

TTM FCF of $81.85M on $197.07M in operating cash flow. The FCF / Net Income ratio of -0.6x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 118% — a weakening trend.